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Previous studies have shown that many within-class differences exist between sulfonyl-
ureas (SUs), however, whether differences exist regarding the time it takes between initiat-
ing an SU and the need to intensify treatment with insulin is unclear. The aim of this study
was investigate the relationships between the three frequently used sulphonylureas, pre-
scribed as dual therapy next to metformin, and the time needed to treatment intensification
with either insulin or oral triple therapy in patients with type 2 diabetes mellitus.
Methods
Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) is a prospective
observational cohort study set in primary care in the Netherlands. Annually collected data
on diabetes medication and clinical variables within ZODIAC are used to evaluate the pri-
mary outcome, time to insulin and secondary outcome, time to either insulin or triple oral
therapy. For statistical analysis a time-dependent cox proportional hazard model was used.
Results
3507 patients were included in the analysis, with a mean age of 61 (SD 11.4) and amedian
HbA1c of 6.8% [IQR 6.4–7.4] (50.8mmol/mol [IQR 46.4–57.4]).The hazard ratio (HR) for the pri-
mary endpoint was 1.10 (95%CI 0.78–1.54) for metformin/glimepiride and 0.93 (95%CI 0.67–
1.30) for metformin/tolbutamide with metformin/gliclazide as reference group. The HR for the
secondary outcome was 1.04 (95%CI 0.78–1.40) and 0.85 (95%CI 0.64–1.13), respectively.
Conclusion
In this large Dutch primary care cohort, new users of neither gliclazide, glimepiride nor tolbu-
tamide as dual therapy with metformin, resulted in differences in the time needed for further
treatment intensification.
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Introduction
Many important within-class SU differences have been described, mostly in favour of glicla-
zide. For example; gliclazide is considered the safest SU in patients with renal impairment[1].
Furthermore, there is also a clear benefit of prescribing gliclazide for reasons of hypoglycaemia
risk[2] and possibly cardiovascular safety[3]. Within-class SU differences have also been
described for SU failure rate. For example, glipizide and glibenclamide are associated with a
higher failure rate compared to gliclazide[4]. In the 2013 Dutch type 2 diabetes mellitus
(T2DM) guideline, gliclazide specifically became the preferred sulphonylurea (SU) and the first
intensification step after metformin[5].
When dual oral therapy fails, next to lifestyle interventions, a switch to or addition of, once
daily insulin or possibly a third oral agent are advised steps for regaining adequate glycaemic
control. This moment in time could be considered a turning point for patients and is regarded
as disease progression for patients and therefore is a relevant surrogate endpoint.
Whether within-class differences exist for “time needed to intensification” for SUs remains
unclear. We hypothesized that a difference in time to intensification could be present, since the
subsequent generations of SUs have become increasingly more potent[4,6]. The presence of a
within-class difference concerning time to insulin could benefit both patient related outcomes
as well as aid in controlling health care costs since treatment with oral glucose lowering agents
is more cost-effective than treatment with insulin[7].
Using a new-user design, the aim of this study was to investigate the relationships between
the three most frequently prescribed SUs in the Netherlands, prescribed as dual therapy next to
metformin and the time needed to treatment intensification with either insulin or oral triple
therapy in patients with T2DM.
Methods
The study is reported according to the STROBE (Strengthening the reporting of observational
studies in epidemiology) recommendations[8].
Study design and data collection
This study is part of the prospective ZODIAC (Zwolle Outpatient Diabetes project Integrating
Available Care) cohort study. This ongoing study started in 1998 in the Zwolle region, and has
since expanded to more than 600 general practices in the north-east and western part of the
Netherlands. Following two major expansions of the cohort in 2006 and 2009, the majority of
patients were included from 2006 onwards. Patients included in the study are diagnosed with
T2DM and are exclusively treated in primary care. Data are collected annually by general prac-
titioners and send to the diabetes centre annually.
Patient selection
A “new-user” design[9] was used. Patients who used metformin monotherapy for at least one
year and subsequently intensified for the first time with gliclazide, glimepiride or tolbutamide
were selected. Patients were also required to be included in the ZODIAC study between 1998
and 2012. Patients with an eGFR below 30mL/min/1.73m2 or when eGFR at baseline was miss-
ing were excluded. We hypothesized that including these patients could lead to selection bias
because gliclazide is the preferred SU in renal impairment[1].
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Outcome measures
The primary outcome was the first receipt of insulin and secondary outcome was first receipt
of either insulin or triple oral therapy.
Statistical analysis
Quantitative variables are presented as means with standard deviation for normally distributed
values, and median and interquartile range (IQR) for skewed variables. Time-dependent cox
proportional hazard analyses, adjusted for HbA1c, age, gender, diabetes duration, updated
mean creatinine and updated mean BMI were used to evaluate the primary and secondary out-
come. All analyses were performed with IBM SPSS Statistics (Version 22.0).
Ethics statement
In the ZODIAC study, patients consented to anonymous use of their data for study purposes.
The medical ethics committee of Isala, Zwolle, The Netherlands approved the ZODIAC study
(METC reference numbers 03.0316 and 07.0335).
Results
From the complete cohort (N = 82.167), 25.183 patients used metformin monotherapy. From
these, 4096 received some form of intensification. Patients receiving insulin as second step on
top of metformin (n = 83) and 506 patients with an eGFR< 30 ml/min/1.73m2 or missing
eGFR were excluded (Fig 1). From the 3507 selected patients, 47% was female, the mean age
was 61 (SD 11.4), median HbA1c 6.8% [IQR 6.4–7.4] (50.8 mmol/mol [IQR 46.4–57.4]),
median BMI 29.7 [IQR 26.8–33.3], median diabetes duration 6.8 years [IQR 4.5–9.4], mean
eGFR 83.2 (SD 20.1) and median creatinine 76.0 [IQR 65.0–89.0] (Table 1). There were no
baseline differences in median HbA1c between the different treatment groups; metformin/gli-
clazide 6.9 [IQR 6.4–7.4], metformin/glimepiride 6.8 [IQR 6.3–7.4] and metformin/tolbuta-
mide 6.9 [IQR 6.4–7.5]. Two-and-half and 5 years after intensification 13.0% and 32.0% of
patients were using insulin, respectively. Two-and-half and 5 years after intensification 17.5%
and 39.7% of patients were using either insulin or triple oral therapy, respectively.
Primary endpoint
In the unadjusted model the HR for metformin/glimepiride was 1.15 (95% CI 0.83–1.61) and for
metformin/tolbutamide 0.97 (95% CI 0.70–1.34), with metformin/gliclazide as a reference cate-
gory. There were no significant differences between the three groups in primary outcome (Fig 2).
The pairwise HR's for the primary endpoint in the unadjusted model are shown in Table 2.
The HR for time to insulin using a fully corrected model for metformin/glimepiride was
1.10 (95% CI 0.78–1.54) and for metformin/tolbutamide 0.93 (95% CI 0.67–1.30), with metfor-
min/gliclazide as a reference category. The pairwise HR's for the primary endpoint in the fully
corrected model are shown in Table 3. There were no significant differences between the three
groups in primary outcome. HbA1c and age are significantly associated with the primary end-
point with HRs of 1.08 (95%CI 1.00–1.15) and 0.99 (95%CI 0.97–1.00) respectively. Creatinine,
BMI, gender, and diabetes duration are not significantly associated with the primary endpoint
(Table 3).
Secondary endpoint
In the unadjusted model the HR for metformin/glimepiride was 1.11 (95% CI 0.83–1.48) and
for metformin/tolbutamide 0.88 (95% CI 0.66–1.17), with metformin/gliclazide as a reference
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category. There were no significant differences between the three groups in primary outcome
(Fig 2). The pairwise HR's for the primary endpoint in the unadjusted model are shown in
Table 2.
The HRs for time to insulin or triple oral therapy for metformin/glimepiride was 1.04 (95%
CI 0.78–1.40) and for metformin/tolbutamide 0.85 (95% CI 0.64–1.13) with metformin/glicla-
zide as a reference category. The pairwise HR's for the secondary endpoint are shown in
Table 3. HbA1c (HR 1.08, 95% CI 1.02–1.15) and age (HR 0.98, 95% CI 0.97–1.00) were signifi-
cantly associated with the need for intensification therapy with insulin of a third oral agent.
Risk for time to insulin or triple oral therapy by increased 8% per 1% increase in HbA1c and
decreased 2% per 1 year increase in age. Creatinine, BMI, Gender and diabetes duration were
not significantly associated with the secondary endpoint (Table 3).
Fig 1. Flow of selected patients.
doi:10.1371/journal.pone.0157668.g001
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Discussion
In this primary care cohort of patients who used metformin monotherapy and intensified with
gliclazide, glimepiride or tolbutamide, the so-called new users, there were no statistically signif-
icant differences in time to insulin, or time to either insulin or a third oral agent. After 2.5 and
5 years respectively 13.0% and 32.0% of patients were using insulin and respectively 17.5% and
39.7% of patients were using insulin or triple therapy. The numbers are in accordance with the
numbers found previous studies[10].
Table 1. Baseline characteristics.
Number of patients 3507
Gendera Female: 47%, Male: 53%
Age at diagnosis (years)b 57.8 [17.9]
Age (years)b 61.0 [11.4]
eGFRb 83.2 [20.1]
Creatinine (μmol/L)c 76.0 [65.0–89.0]
Diabetes duration (years)c 6.8 [4.5–9.4]
HbA1c (%) / HbA1c (mmol/mol) c 6.8 [6.4–7.4] / 50.8 [46.4–57.4]
BMIc 29.7 [26.8–33.3]
a%
b mean with SD
c median with interquartile range
doi:10.1371/journal.pone.0157668.t001
Fig 2. Cumulative survival. Panel A shows the cumulative survival for gliclazide, glimepiride and tolbutamide and time to insulin using the unadjusted
model. Panel B shows the cumulative survival for gliclazide, glimepiride and tolbutamide and time to insulin or triple oral therapy using the unadjusted
model.
doi:10.1371/journal.pone.0157668.g002
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No studies were found investigating within-class differences in time to insulin in patients
using metformin and a SU as dual therapy. A retrospective cohort study conducted in Colom-
bia showed a higher risk of insulin treatment (OR = 3.49, 95%CI 2.61–4.66) in patients treated
with metformin and glibenclamide[11]. In a Swedish retrospective cohort study the probability
of insulin use was increased (HR = 2.71, 95%CI: 2.15–3.43) in patients using more than one
oral antidiabetic agent[12]. However, the risk of insulin use was not evaluated in individual
agents within the SU class.
Based on the results of this study, that in daily primary care practice, the time to intensifica-
tion with insulin or a third oral agent is not influenced by the choice of a specific SU but rather
by specific patient characteristics despite the differences in potency between the three SUs[4,6].
In this study, HbA1c and age appeared to be more important factors.
The strengths of this study were the inclusion of patients from a daily care setting and the
new-user design. The daily care setting increases the generalizability of our results. Excluding
prevalent users allowed us to avoid underascertainment of insulin prescription that occurs
early after the start of SUs and also allowed us to avoid that confounders are influenced by pre-
vious treatment[9]. A limitation was that the data is collected annually; changes in medication
within this year might not be reflected in our database. A second limitation is the possibility
that patients who required insulin could have been referred to secondary care. Patients within
ZODIAC are lost to follow-up when referred to secondary care for their diabetes treatment.
However, in the Netherlands insulin treatment is usually initiated in primary care and thus
Table 2. Unadjustedmodel.
Time to insulin Time to insulin or third oral agent
HR 95% CI p HR 95% CI p
Medication 0.429 0.161
Gliclazide* vs Glimepiride 1.151 0.825–1.605 0.407 1.111 0.834–1.480 0.470
Glicazide* vs Tolbutamide 0.965 0.695–1.340 0.831 0.878 0.660–1.168 0.371
Glimepiride* vs Tolbutamide 0.838 0.637–1.103 0.207 0.790 0.620–1.006 0.056
*Reference category.
doi:10.1371/journal.pone.0157668.t002
Table 3. Covariates included in Cox proportional hazardmodel.
Time to insulin Time to insulin or third oral agent
HR 95% CI p HR 95% CI p
HbA1c 1.077 1.008–1.151 0.028 1.082 1.022–1.145 0.007
Creatinine 0.998 0.990–1.006 0.688 0.992 0.985–1.000 0.410
BMI 1.007 0.983–1.033 0.585 1.021 1.000–1.043 0.510
Gender 1.012 0.768–1.334 0.934 0.896 0.701–1.145 0.380
Diabetes duration 0.988 0.951–1.026 0.545 0.994 0.969–1.020 0.644
Age 0.986 0.974–0.998 0.026 0.984 0.974–0.995 0.003
Medication 0.541 0.234
Gliclazide* vs Glimepiride 1.095 0.780–0.537 0.602 1.044 0.780–1.397 0.772
Glicazide* vs Tolbutamide 0.933 0.668–1.304 0.684 0.848 0.635–1.134 0.266
Glimepiride* vs Tolbutamide 0.852 0.643–1.131 0.268 0.813 0.634–1.041 0.101
* reference category
doi:10.1371/journal.pone.0157668.t003
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expect the underestimation of time to insulin to be limited. Furthermore, patients could have
refused intensification of therapy like the addition of insulin, leading to an underestimation of
the primary endpoint which was the reason for also analysing the time needed to a third oral
agent. However, we don’t expect a between-group difference in motivation to use insulin.
Conclusion
In conclusion, there were no differences found in this large Dutch primary care cohort with
respect to the time needed for further treatment intensification with neither insulin nor a third
oral agent when treated with gliclazide, glimepiride or tolbutamide on top of metformin. In
this study higher HbA1c and lower age are associated with a shorter time needed to insulin and
a shorter time to a third oral agent.
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